Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 14, 2019
SenzaGen Gains First Patent for GARDpotency
Author(s)Pharmaceutical Technology Editors
SenzaGen has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.
Advertisement
Swedish-based company, SenzaGen, has revealed that is has been granted a patent in Europe for GARDpotency, a testing application that enables the measurement of the allergenicity of chemical substances without animal research.
“Getting this patent approved for the European market is commercially interesting, as there is a ban within the European Union on the sale of animal-tested cosmetic products,” said Anki Malmborg Hager, CEO of SenzaGen, in a June 13, 2019 press statement. “Furthermore, to quantify how strong the allergenic effect is according to classification and labeling (CLP/GHS) is a requirement in the EU chemical regulation REACH [Registration, Evaluation, Authorization, and Restriction of Chemicals]. As the only company in the world, SenzaGen can now offer an animal-free test method for this.”
The company’s GARD portfolio of products comprises a set of allergy tests that are performed on human cells in-vitroin combination with artificial intelligence, which can be used to replace animal testing in various industries, including pharma. There are several other ongoing patent applications for GARDpotency and other products in the portfolio.
Source:
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement